A long-acting β2-adrenergic agonist increases the expression of muscarine cholinergic subtype‑3 receptors by activating the β2-adrenoceptor cyclic adenosine monophosphate signaling pathway in airway smooth muscle cells

Liu,Yuan‑Hua; Wu,Song‑Ze; Wang,Gang; Huang,Ni‑Wen; Liu,Chun‑Tao

doi:10.3892/mmr.2015.3307

A long-acting β2-adrenergic agonist increases the expression of muscarine cholinergic subtype‑3 receptors by activating the β2-adrenoceptor cyclic adenosine monophosphate signaling pathway in airway smooth muscle cells

Authors:
- Yuan‑Hua Liu
- Song‑Ze Wu
- Gang Wang
- Ni‑Wen Huang
- Chun‑Tao Liu
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: February 5, 2015 https://doi.org/10.3892/mmr.2015.3307
Pages: 4121-4128
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The persistent administration of β2‑adrenergic (β2AR) agonists has been demonstrated to increase the risk of severe asthma, partly due to the induction of tolerance to bronchoprotection via undefined mechanisms. The present study investigated the potential effect of the long‑acting β2‑adrenergic agonist, formoterol, on the expression of muscarinic M3 receptor (M3R) in rat airway smooth muscle cells (ASMCs). Primary rat ASMCs were isolated and characterized following immunostaining with anti‑α‑smooth muscle actin antibodies. The protein expression levels of M3R and phospholipase C‑β1 (PLCβ1) were characterized by western blot analysis and the production of inositol 1,4,5‑trisphosphate (IP3) was determined using an enzyme‑linked immunosorbent assay. Formoterol increased the protein expression of M3R in rat ASMCs in a time‑ and dose‑dependent manner, which was significantly inhibited by the β2AR antagonist, ICI118,551 and the cyclic adenosine monophosphate (cAMP) inhibitor, SQ22,536. The increased protein expression of M3R was positively correlated with increased production of PLCβ1 and IP3. Furthermore, treatment with the glucocorticoid, budesonide, and the PLC inhibitor, U73,122, significantly suppressed the formoterol‑induced upregulated protein expression levels of M3R and PLCβ1 and production of IP3. The present study demonstrated that formoterol mediated the upregulation of M3R in the rat ASMCs by activating the β2AR‑cAMP signaling pathway, resulting in increased expression levels of PLCβ1 and IP3, which are key to inducing bronchoprotection tolerance. Administration of glucocorticoids or a PLC antagonist prevented formoterol‑induced bronchoprotection tolerance by suppressing the protein expression of M3R.

View Figures

View References

1	Beasley R, Crane J, Lai CK and Pearce N: Prevalence and etiology of asthma. J Allergy Clin Immunol. 105:S466–S472. 2000. View Article : Google Scholar : PubMed/NCBI
2	Pakhale S, Mulpuru S and Boyd M: Optimal management of severe/refractory asthma. Clin Med Insights Circ Respir Pulm Med. 5:37–47. 2011.PubMed/NCBI
3	Myers TR and Tomasio L: Asthma: 2015 and beyond. Respir Care. 56:1389–1407. 2011. View Article : Google Scholar : PubMed/NCBI
4	Perez JF and Sanderson MJ: The frequency of calcium oscillations induced by 5-HT, ACH, and KCl determine the contraction of smooth muscle cells of intrapulmonary bronchioles. J Gen Physiol. 125:535–553. 2005. View Article : Google Scholar : PubMed/NCBI
5	García-Marcos L, Schuster A and Cobos Barroso N: Inhaled corticosteroids plus long-acting β2-agonists as a combined therapy in asthma. Expert Opin Pharmacother. 4:23–39. 2003. View Article : Google Scholar
6	Wijesinghe M, Perrin K, Harwood M, Weatherall M and Beasley R: The risk of asthma mortality with inhaled long acting β-agonists. Postgrad Med J. 84:467–472. 2008. View Article : Google Scholar : PubMed/NCBI
7	Vathenen AS, Knox AJ, Higgins BG, Britton JR and Tattersfield AE: Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet. 1:554–558. 1988. View Article : Google Scholar : PubMed/NCBI
8	Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R and Meyer RJ: Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 124:70–74. 2003. View Article : Google Scholar : PubMed/NCBI
9	Haney S and Hancox RJ: Rapid onset of tolerance to β-agonist bronchodilation. Respir Med. 99:566–571. 2005. View Article : Google Scholar : PubMed/NCBI
10	Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP and Taylor DR: Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J. 17:368–373. 2001. View Article : Google Scholar : PubMed/NCBI
11	Wraight JM, Hancox RJ, Herbison GP, Cowan JO, Flannery EM and Taylor DR: Bronchodilator tolerance: the impact of increasing bronchoconstriction. Eur Respir J. 21:810–815. 2003. View Article : Google Scholar : PubMed/NCBI
12	Giembycz MA and Newton R: Beyond the dogma novel β2-adrenoceptor signalling in the airways. Eur Respir J. 27:1286–1306. 2006. View Article : Google Scholar : PubMed/NCBI
13	Goncharova EA, Goncharov DA, Zhao H, Penn RB, Krymskaya VP and Panettieri RA Jr: β2-adrenergic receptor agonists modulate human airway smooth muscle cell migration via vasodilator-stimulated phosphoprotein. Am J Respir Cell Mol Biol. 46:48–54. 2012. View Article : Google Scholar : PubMed/NCBI
14	McGraw DW, Almoosa KF, Paul RJ, Kobilka BK and Liggett SB: Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox. J Clin Invest. 112:619–626. 2003. View Article : Google Scholar : PubMed/NCBI
15	Chilvers ER, Lynch BJ and Challiss RA: Dissociation between β-adrenoceptor-mediated cyclic AMP accumulation and inhibition of histamine-stimulated phosphoinositide metabolism in airways smooth muscle. Biochem Pharmacol. 53:1565–1568. 1997. View Article : Google Scholar : PubMed/NCBI
16	Mitchell RW, Halayko AJ, Kahraman S, Solway J and Wylam ME: Selective restoration of calcium coupling to muscarinic M(3) receptors in contractile cultured airway myocytes. Am J Physiol Lung Cell Mol Physiol. 278:L1091–L1100. 2000.PubMed/NCBI
17	Tronde A, Gillen M, Borgstrom L, Lotvall J and Ankerst J: Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J Clin Pharmacol. 48:1300–1308. 2008. View Article : Google Scholar : PubMed/NCBI
18	Katsunuma T, Roffel AF, Elzinga CR, Zaagsma J, Barnes PJ and Mak JC: β(2)-adrenoceptor agonist-induced upregulation of tachykinin NK(2) receptor expression and function in airway smooth muscle. Am J Respir Cell Mol Biol. 21:409–417. 1999. View Article : Google Scholar : PubMed/NCBI
19	Mak JC, Roffel AF, Katsunuma T, Elzinga CR, Zaagsma J and Barnes PJ: Up-regulation of airway smooth muscle histamine H(1) receptor mRNA, protein, and function by β(2)-adrenoceptor activation. Mol Pharmacol. 57:857–864. 2000.PubMed/NCBI
20	Song KS, Lee TJ, Kim K, Chung KC and Yoon JH: cAMP-responding element-binding protein and c-Ets1 interact in the regulation of ATP-dependent MUC5AC gene expression. J Biol Chem. 283:26869–26878. 2008. View Article : Google Scholar : PubMed/NCBI
21	Lincoln TM, Dey N and Sellak H: Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol (1985). 91:1421–1430. 2001.
22	de Rooij J, Zwartkruis FJ, Verheijen MH, et al: Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 396:474–477. 1998. View Article : Google Scholar : PubMed/NCBI
23	Sayers I, Swan C and Hall IP: The effect of β2-adrenoceptor agonists on phospholipase C (β1) signalling in human airway smooth muscle cells. Eur J Pharmacol. 531:9–12. 2006. View Article : Google Scholar : PubMed/NCBI
24	Chong LK, Chowdry J, Ghahramani P and Peachell PT: Influence of genetic polymorphisms in the β2-adrenoceptor on desensitization in human lung mast cells. Pharmacogenetics. 10:153–162. 2000. View Article : Google Scholar : PubMed/NCBI
25	Kotlikoff MI and Kamm KE: Molecular mechanisms of β-adrenergic relaxation of airway smooth muscle. Annu Rev Physiol. 58:115–141. 1996. View Article : Google Scholar
26	Kume H, Hall IP, Washabau RJ, Takagi K and Kotlikoff MI: β-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and -independent mechanisms. J Clin Invest. 93:371–379. 1994. View Article : Google Scholar : PubMed/NCBI
27	Adcock IM, Maneechotesuwan K and Usmani O: Molecular interactions between glucocorticoids and long-acting β2-agonists. J Allergy Clin Immunol. 110:S261–S268. 2002. View Article : Google Scholar : PubMed/NCBI
28	Lasserson TJ, Ferrara G and Casali L: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev. 7:CD0041062011.